Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
Sign Up to like & getrecommendations! Published in 2021 at "Calcified tissue international"
DOI: 10.1007/s00223-020-00785-1
Abstract: Discontinuation of denosumab treatment is associated with rapid bone loss that could be prevented in many patients by zoledronate (ZOL) infusion given 6 months after the last denosumab injection. The effects, however, of zoledronate administration… read more here.
Keywords: versus months; early zol; zol infusion; zol ... See more keywords
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.08.020
Abstract: PURPOSE The development of treatment-related adverse events (trAE) correlates favorably with clinical outcomes in multiple studies of patients receiving immune checkpoint inhibitors (ICI); however, this relationship is undefined in patients with hepatocellular carcinoma (HCC). PATIENTS… read more here.
Keywords: versus months; routine practice; clinical trials; cancer ... See more keywords
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2017.02.001
Abstract: Introduction: Little is known about the prevalence, prognosis, and response to treatment of advanced NSCLC harboring multiple genomic alterations. Methods: The French Biomarkers France database, which includes 17,664 patients, was used. The prevalence of multiple… read more here.
Keywords: versus months; multiple molecular; harboring multiple; patients harboring ... See more keywords
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR‐Mutated Advanced NSCLC
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.10.150
Abstract: Introduction: EGFR‐mutant NSCLC displays diverse outcomes to tyrosine kinase inhibitor (TKI) treatment. Because co‐occurring genomic alterations might describe different biological subsets of patients with this cancer, exploring co‐occurring genomic alterations that impact patients’ outcomes using… read more here.
Keywords: versus months; egfr; pfs versus; cohort ... See more keywords
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.08.009
Abstract: BACKGROUND Most studies on MET exon 14 (MET-ex14) alteration, defined as an oncogenic driver, have been carried out among Caucasians; similar studies among Chinese people are limited. METHODS We retrospectively analyzed the genomic profiles of… read more here.
Keywords: versus months; met ex14; clinical outcomes; months versus ... See more keywords
Is Longer Treatment Better? A Comparison Study of 3 Versus 6 Months Cognitive Remediation in Schizophrenia
Sign Up to like & getrecommendations! Published in 2017 at "Neuropsychology"
DOI: 10.1037/neu0000347
Abstract: Objective: Despite its extensive use for treating cognitive deficits in schizophrenia, computer-assisted cognitive remediation (CACR) currently lacks a standardized protocol. Duration is an important feature to be defined, as it may contribute to heterogeneous outcome.… read more here.
Keywords: versus months; schizophrenia; treatment; cognitive remediation ... See more keywords
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Cancer"
DOI: 10.1038/s41416-018-0164-0
Abstract: BackgroundIn the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy.MethodsOutcomes were evaluated… read more here.
Keywords: versus months; versus everolimus; versus; cabozantinib versus ... See more keywords
Pembrolizumab improves OS across PD-L1 subgroups
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-019-0213-5
Abstract: in 2016, KeYNOte-024 established the superior efficacy of first-line pembrolizumab over chemotherapy for metastatic non-small-cell lung cancer (NsCLC) with a programmed cell death 1 ligand 1 (PD-L1) tumour proportion score (tPs) ≥50%. Now, overall survival… read more here.
Keywords: versus months; chemotherapy; pembrolizumab improves; across subgroups ... See more keywords
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdy333
Abstract: Abstract Background We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). Patients and methods ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in… read more here.
Keywords: versus months; months versus; treatment; alk rearranged ... See more keywords
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-2980
Abstract: Purpose: Pembrolizumab demonstrated efficacy in PD-L1–positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (G/GEJ) cancer in the first-, second-, and third-line setting in KEYNOTE-062, KEYNOTE-061, and KEYNOTE-059, respectively. To better delineate the specificity of… read more here.
Keywords: months versus; combined positive; efficacy; versus months ... See more keywords
Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359231156387
Abstract: Background: Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (IO)… read more here.
Keywords: disease; metastatic nsclc; versus months; treatment ... See more keywords